Related Experiment Video
Updated: Jul 29, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
[Inhaled insulin, new perspective for insulin therapy]
1Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Sart Tilman, 4000 Liège, Belgique. Regis.Radermecker@ulg.ac.be
Revue Medicale De Liege
|July 23, 2005
Summary
Inhaled insulin offers a potential alternative to subcutaneous injections for diabetes management, improving patient compliance. Further research is needed on efficacy, safety, and cost-effectiveness compared to newer insulin analogues.
Area of Science:
- Endocrinology
- Pharmacology
- Pulmonary Medicine
Context:
- Subcutaneous insulin injections are the standard for diabetes care.
- Patient reluctance and compliance issues often hinder effective insulin therapy.
- Alternative insulin delivery methods are actively being explored to improve patient outcomes.
Purpose:
- To review different insulin pulmonary delivery devices.
- To compare preliminary data of inhaled insulin versus subcutaneous injections.
- To identify challenges and future research directions for inhaled insulin therapy.
Summary:
- Inhaled insulin presents a promising alternative to traditional subcutaneous injections, potentially enhancing patient compliance and treatment intensification.
- Various pulmonary delivery devices are under investigation, with preliminary data suggesting comparability to human regular insulin.
- Key challenges include identifying effective bioavailability enhancers, addressing cost concerns, and conducting rigorous long-term safety studies, particularly regarding pulmonary toxicity.
Impact:
- Inhaled insulin could significantly improve the quality of life for individuals with diabetes by offering a less invasive administration route.
- Successful development may lead to wider adoption of intensified insulin therapies, improving glycemic control.
- Ongoing research and pharmaceutical investment highlight the significant potential of inhaled insulin in diabetes care.
Related Concept Videos
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...